Related Experiment Videos
Effects of CS-518, a thromboxane synthase inhibitor, on eosinophil function
1Biological Research Laboratories, Sankyo Co., Ltd., Tokyo, Japan.
European Journal of Pharmacology
|August 3, 1993
Summary
CS-518, a thromboxane A2 synthase inhibitor, effectively reduced eosinophil accumulation and activation in an asthma model. This compound shows potential for treating eosinophil-related inflammatory conditions.
Area of Science:
- Pharmacology
- Immunology
- Respiratory Medicine
Background:
- Eosinophils play a key role in asthma pathogenesis.
- Thromboxane A2 (TXA2) and prostaglandin I2 (PGI2) are implicated in eosinophil function.
- Inhibitors of TXA2 synthase may modulate eosinophil responses.
Purpose of the Study:
- To investigate the effects of CS-518, a TXA2 synthase inhibitor, on eosinophil accumulation and activation.
- To evaluate CS-518's efficacy in an experimental asthma model and cellular systems.
Main Methods:
- In vivo studies using an experimental asthmatic guinea pig model.
- In vitro studies on guinea pig eosinophils.
- Assessment of eosinophil accumulation in bronchoalveolar lavage fluid.
- Measurement of TXA2 and PGI2 production.
- Evaluation of eosinophil functions: chemotaxis, peroxidase release, and superoxide generation.
Main Results:
- CS-518 potently inhibited early-phase eosinophil accumulation and less so in the delayed phase.
- CS-518 completely inhibited eosinophil hypodensity in the delayed phase, even at lower doses.
- CS-518 suppressed TXA2 production and potentiated PGI2 production by eosinophils.
- CS-518 and PGI2 inhibited eosinophil chemotaxis, peroxidase release, and superoxide generation.
Conclusions:
- CS-518 is a potent inhibitor of eosinophil activation.
- TXA2 and PGI2 are involved in modulating eosinophil function.
- CS-518 demonstrates potential therapeutic value for asthma and other eosinophil-mediated inflammatory diseases.